Mergers & Acquisitions
Filter News
Found 20,965 articles
-
Data from a Phase III trial of apraglutide for a type of short bowel syndrome with intestinal failure is expected by the end of the year. It is also in a Phase II study for acute graft-versus-host disease. -
Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd
5/22/2023
Freenome announced it has acquired Oncimmune Ltd, a UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT Lung blood test, autoantibody platform and research and development pipeline of 7+ cancer detection signatures.
-
Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale
5/22/2023
Enzo Biochem, Inc., announced that the preliminary voting results from the Inspector of Election at today’s Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a majority of Enzo’s outstanding common stock.
-
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
5/22/2023
Ironwood Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement for Ironwood to acquire VectivBio for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of approximately $1 billion, net of VectivBio cash and debt (the “Transaction”).
-
IDEX Corporation Completes Acquisition of Iridian Spectral Technologies
5/22/2023
IDEX Corporation announced that it has completed its previously-announced acquisition of Iridian Spectral Technologies, a global leader in designing and manufacturing thin-film, multi-layer optical filters.
-
Calyxt Announces Stockholder Approval of Merger With Cibus
5/19/2023
Calyxt, Inc. announced the results of the special meeting of its stockholders held on May 18, 2023.
-
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
5/18/2023
Biodexa Pharmaceuticals PLC is pleased to announce that it has signed non-binding letter of intent to potentially acquire Varian Biopharmaceuticals, Inc. (“VarianBio”), a private US precision oncology company developing novel therapeutics for the treatment of cancer.
-
Oncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment
5/18/2023
Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload.
-
Alimera Acquires U.S. Commercial Rights to YUTIQ®
5/18/2023
Alimera Sciences, Inc. today announced its acquisition of additional commercialization rights for YUTIQ (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye from EyePoint Pharmaceuticals, Inc. (EyePoint).
-
The Federal Trade Commission filed a lawsuit Tuesday seeking an injunction to prevent Amgen’s buyout of Horizon Therapeutics, which the agency says would “entrench monopoly drugs.” -
Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
5/16/2023
Horizon Therapeutics plc issued the following statement in response to the FTC’s complaint seeking to block Amgen’s proposed acquisition of the Company.
-
Amgen Responds to FTC Action Re: Proposed Acquisition of Horizon Therapeutics
5/16/2023
Amgen issued the following statement in response to the U.S. Federal Trade Commission's complaint seeking to block the company's proposed acquisition of Horizon Therapeutics plc:.
-
Waters Corporation Completes Acquisition of Light Scattering Leader Wyatt Technology
5/16/2023
Waters™ Corporation announced it has completed its acquisition of Wyatt Technology, a pioneer and well-recognized leader in innovative light scattering and field-flow fractionation instruments, software, accessories, and services.
-
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
5/16/2023
BELLUS Health Inc. announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting of shareholders of BELLUS on June 16, 2023.
-
Juno Pharmaceuticals Acquires Omega Laboratories, Propelling Canada’s Pharmaceutical Industry Forward
5/15/2023
Today, Juno Pharmaceuticals Canada announced the acquisition of Omega Laboratories (“Omega”), one of Canada’s largest domestic specialty injectable pharmaceutical manufacturers.
-
PARI acquires Nortev, the manufacturer of the equine inhaler Flexineb®
5/15/2023
PARI, manufacturer of medical devices and pharmaceuticals in the field of respiratory and inhalation, today announced the acquisition of the Irish company Nortev.
-
ERYTECH Provides Update on the Announced Combination with PHERECYDES
5/15/2023
ERYTECH Pharma,aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided anupdateon the announced combination with PHERECYDES.
-
Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge
5/12/2023
Hoth Therapeutics, Inc., a patient focused biopharmaceutical company, announced that they have entered into a mutual agreement with Algorithm Sciences, Inc. to terminate their previously announced decision to merge, originally announced on April 26, 2023.
-
Walgreens Boots Alliance Sells Shares of AmerisourceBergen Corporation for $694 Million of Initial Proceeds
5/12/2023
Walgreens Boots Alliance, Inc. announced that it has sold shares of AmerisourceBergen Corporation common stock pursuant to variable prepaid forward transactions executed in reliance on Rule 144 of the Securities Act of 1933, as amended, for current proceeds of approximately $644 million.
-
The biopharma company scored two major wins on Tuesday: a court victory over HIV patent claims and an acquisition deal to expand its pipeline in cancer and inflammatory diseases.